Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Aegis Capital analyst David Bouchey reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $7.2 price target.
- Meeting date aligns with prior guidance -- FDA to review AEON's analytical development plan and initial data -
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(11.52)...
